A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer - Wikidata - wikimedia - TriplyDB

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

http://www.wikidata.org/entity/Q36694899

about

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer.Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.Capecitabine in gastric cancer.Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice Recent advances in chemotherapy for advanced gastric cancer Chemotherapy for advanced gastric cancer: across the years for a standard of care.Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression.Clinical and experimental study of oxaliplatin in treating human gastric carcinoma Recent developments in chemotherapy of advanced gastric cancer.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.Docetaxel in the treatment of gastric cancer.Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites.Capecitabine in advanced gastric cancer.Dual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity.Current approaches to gastric cancer in Korea.Capecitabine in the treatment of advanced gastric cancer.Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer.Emerging role of capecitabine in gastric cancer.Chemotherapy for advanced gastric cancer: slow but further progress.Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.Capecitabine for the treatment of gastric cancer.Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen.A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.

P2860

Q33386694-80967F9C-A4AD-44D0-B18F-7C331B85ADA6 Q33778285-85B428D3-DE8C-4EED-B17B-0A7355591985 Q34010159-053E86EB-7750-4670-91B0-D5E5AE96CEA3 Q34236005-D8991611-F791-4851-84FD-04A4EC5D3244 Q34255969-3C9296DF-6236-4B04-999C-6FCFF46352C8 Q34389753-B89ADEF5-F676-4A94-BC37-1AA58285442A Q34617795-1272F582-F53D-4A4D-8BEB-157E07D8BC5A Q35208094-6E222083-91F7-4D93-B951-DAD09E391F92 Q35951880-69C0AAF3-659C-41E6-9031-701590B02A83 Q36065649-A9DE0A3B-157D-4C11-B7C3-E7176D5C23DB Q36090047-256073D0-18E0-43C0-94CB-5A5A816A3845 Q36376439-EA0E575B-E358-4BA2-845B-758FA8FA4C79 Q36402491-CFDC71C9-23F0-4D0C-8C67-8AB4B8AC3208 Q36613622-CA49246A-8A69-48C0-B9DD-AC94805F3E1B Q36614036-8665B75A-90F6-4166-9509-B28BAEDC020E Q36614248-96C1931C-DFDF-49FD-A059-DF02BECF7D94 Q36614394-B2AA671D-0FD3-4223-BB4A-D884055EDD86 Q36614734-BD865447-7AA4-4550-AA09-61424C1AB22C Q36615597-BFF825FD-5B58-4ABF-8374-614DA6018AB9 Q36616011-DB062A4D-AD5C-4497-8B24-3BB08C505B32 Q36616503-A2B39D5F-D0B3-4208-92BF-BF946FE84FB3 Q36628679-4DC5EFD2-C7A9-41EB-843C-41327CA1E002 Q36979346-B6144741-11AA-4F95-8F4B-10FBEBD1F557 Q37023985-A9B5B56B-ECCA-4125-B1B9-781224ED3F05 Q37077836-CA73FDA1-FB99-411E-B856-98C34996C614 Q37136996-2D0FBE4C-78B7-497B-ABA4-B672F18B0E8F Q37236380-507DF8DC-C91D-44BD-A9D9-99DF206E2391 Q37403462-B86C7884-5AB7-46CE-A49E-0B563D2FF893 Q37446941-42D3B787-7B97-437D-B2D9-2E4895748681 Q37477979-50C2CD1A-7E8D-4855-80E8-ABB189343476 Q37732285-DB1E95A1-B02D-4218-A4B4-EB90ABD65684 Q38608072-3F4470FD-96EC-44D5-9B36-D82E9E5E8689 Q40282337-CC26FBE5-E908-41BD-911E-3D872BA6D5D6 Q40343915-69422E75-EE9C-4A46-8F9E-3E25337B4156 Q40349569-EE52C4B6-5512-4546-A54F-4B2123B7AF72 Q46592440-E83F77C2-E5CA-415B-B5A1-7E9B2DD60435 Q47168501-DA7E411B-9651-4D66-9E01-489DEBA66BBB Q52682114-D6CA6C7A-2DF7-42A1-9469-92D4EB8B8E33

P2860

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

http://www.wikidata.org/entity/Q36694899

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

A phase II study of capecitabi ...... s with advanced gastric cancer

@ast

A phase II study of capecitabi ...... s with advanced gastric cancer

@en

type

label

A phase II study of capecitabi ...... s with advanced gastric cancer

@ast

A phase II study of capecitabi ...... s with advanced gastric cancer

@en

prefLabel

A phase II study of capecitabi ...... s with advanced gastric cancer

@ast

A phase II study of capecitabi ...... s with advanced gastric cancer

@en

P1433

Q36694899-69E5D874-25D6-40BA-86B5-C11C86CF72C7

P1476

Q36694899-D976C813-883B-4300-8147-C973129A92B9

P2093

Q36694899-69167A43-2FA2-4002-AE2A-50E1F60307DC

Q36694899-6E9091D9-A0D0-4A0C-913B-06E2C467B50A

Q36694899-D8472DEB-2180-4357-A370-BAA1D16C7886

Q36694899-D8CFF1A1-7B85-49C5-9CB0-F79CF85D5662

P2860

Q36694899-015D0A4C-CC0B-4DBE-A7E1-7C34EE724089

Q36694899-0DDE8501-25A6-467E-BD75-973FC4659938

Q36694899-19CECA23-38DE-4F4F-8112-D6FB706889B9

Q36694899-373CD17D-755A-410B-908D-878A62E48C45

Q36694899-5997F989-4994-42ED-A7C2-1CED3AD1ABA9

Q36694899-6A840F06-88BF-44D5-89B0-AAAABE3F68F4

Q36694899-7971E794-F77B-4522-BD94-B5CF6E7D67CD

Q36694899-7F005BB7-2A81-4914-B579-8304ACC561B1

Q36694899-81821828-F48D-41F9-A6D8-2DF055BD90CF

Q36694899-B4E2AE3C-5D8F-4ACC-ABEF-7B73C3E9CF12

P2888

Q36694899-1A27E182-1F25-43ED-A1A0-78FEFA351581

P304

Q36694899-2AFA0904-CDAE-4B2D-82D3-3684C44763F1

P31

Q36694899-B4A248A3-F863-4AD5-B4FF-60E9D7A2A569

P356

Q36694899-C3EE7EDC-A811-454F-97F1-EAE14CB41C51

P407

Q36694899-2E673A68-6FEB-4666-A29E-48B2B0C0C13F

P433

Q36694899-48CCF336-8496-4915-8ABC-254EF85D13F7

P478

Q36694899-9550F583-ECF2-487E-BD33-AD206EEAEA2D

P577

Q36694899-79E8F61B-DCF8-41E5-9A47-2F855E8BE68E

P5875

Q36694899-C1A8FDDF-1EE4-4625-8923-D18CD786122A

P698

Q36694899-69810B58-4352-41F0-BF15-707C563CF109

P921

Q36694899-2C7DAEBA-5C2E-498F-87D3-5C9E687D554A

P932

Q36694899-A715FA3D-F4F8-43F2-B612-D95E181B7629

P356

P1433

British Journal of Cancer

P1476

A phase II study of capecitabi ...... s with advanced gastric cancer

@en

P2093

B-Y Ryoo

http://www.w3.org/2001/XMLSchema#string

H-T Kim

http://www.w3.org/2001/XMLSchema#string

S-J Choi

http://www.w3.org/2001/XMLSchema#string

Y H Park

http://www.w3.org/2001/XMLSchema#string

P2860

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.

Docetaxel in advanced gastric cancer.

P2888

P304

1329-1333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601724

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8647640

http://www.w3.org/2001/XMLSchema#string

P698

15054450

http://www.w3.org/2001/XMLSchema#string

P921

P932

2409690

http://www.w3.org/2001/XMLSchema#string